Relationship Between Patient’s Body Mass Index and Dalbavancin’s Effectiveness in the Treatment of Invasive Gram-Positive Infections
Annals of Pharmacotherapy · 2025
DOI: 10.1177/10600280251389823 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Lisa Avery und 3 weiteren Autor:innen. Beteiligte Einrichtung: St. Joseph's Health, Syracuse, NY, USA. Hauptthemen laut MEDLINE: Teicoplanin, Anti-Bacterial Agents, Body Mass Index, Gram-Positive Bacterial Infections. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background
Dalbavancin’s pharmacokinetic parameters suggest obesity may affect serum and tissue concentrations, but currently there is no outcome data in the obese population with invasive infections.
Objective
The purpose of this study is to determine whether body mass index (BMI) correlates with dalbavancin 90-day treatment failure (TF) in patients with invasive infections.
Methods
A multicenter, retrospective observational study analyzed adult patients who received one or more dose of dalbavancin 1500 mg for an invasive infection at 2 community teaching hospitals. Patients admitted ≥3 times within 90 days or received ≥28 days of intravenous antibiotics prior to the initiation of dalbavancin were excluded. The primary outcome was TF at 90 days defined as the need for additional antibiotics or surgery, intolerance, readmission, death, or lost to follow-up. Logistic regression models tested the relationship between BMI and TF. A secondary analysis removed patients lost to follow-up. A conditional probability plot was generated to display the relationship of BMI and TF.
Results
Of 197 patients, 159 met inclusion criteria. Demographics included 64.8% males (n = 103), median age 46 years (34.5-60), and 48.4% (N = 77) persons who inject drugs. Bone/joint accounted for 50% (N = 80) of infections, with Staphylococcus aureus commonly isolated (N = 108, 67.9%). Sixty-eight patients experienced TF. The median BMI in the TF versus cure group was 26.0 kg/m 2 (21.0-30.3) and 26.0 kg/m 2 (23.0-30.5), P = 0.56. Significant predictors in the model included hospital site (OR = 0.28, 95% CI: 0.08-0.95) and methicillin-resistant S. aureus (OR = 3.01, 95% CI: 1.43-6.34). BMI was not a predictor of TF in the primary (OR = 1.00, 95% CI: 0.96-1.05) or secondary analysis (OR = 1.02, 95% CI: 0.97-1.07). The conditional probability plot found no relationship between BMI and TF in BMI
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- St. Joseph's Health, Syracuse, NY, USA.
- Wegmans School of Pharmacy, St. John Fisher University, Rochester, NY, USA.
- School of Arts and Sciences, University of Rochester, Rochester, NY, USA.
- Highland Hospital, UR Medicine, Rochester, NY, USA.
ORCID-Profile: Lisa Avery
Zitieren
APA
Avery, L., Kufel, J., Blaine, B., & Slish, J. (2025). Relationship Between Patient’s Body Mass Index and Dalbavancin’s Effectiveness in the Treatment of Invasive Gram-Positive Infections. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251389823
Vancouver
Avery L, Kufel J, Blaine B, Slish J. Relationship Between Patient’s Body Mass Index and Dalbavancin’s Effectiveness in the Treatment of Invasive Gram-Positive Infections. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280251389823
BibTeX
@article{Avery2025,
author = {Avery, Lisa and Kufel, Julia and Blaine, Bruce and Slish, Judianne},
title = {Relationship Between Patient’s Body Mass Index and Dalbavancin’s Effectiveness in the Treatment of Invasive Gram-Positive Infections},
journal = {Annals of Pharmacotherapy},
year = {2025},
doi = {10.1177/10600280251389823}
}
EUVIMED